Browse Articles

Discover research articles across all indexed journals

Exploring the efficacy of belzutifan in the treatment of renal cell carcinoma associated with von Hippel-Lindau disease: A comparative analysis with external control arm.

Journal of Clinical Oncology W Marston Linehan, Thomas Jemielita, Jerry Cornell et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.469

469 Background: Randomized controlled trials are the gold standard for demonstrating treatment efficacy but are not feasible in certain disease settings. In such cases, external control arm (ECA) analysis can be an effective way to interpret experimental treatment results. Our aim, based on a natural history study (NHS), was to develop an ECA for a Phase 2 single-arm trial (LITESPARK [LS]-004) for belzutifan in 61 patients with VHL disease-associated RCC. With a median follow-up of 37.8 months in LS-004, the objective response rate (ORR) for VHL RCC patients was 64% (95%CI: 50.6, 75.8) and the median time to surgery (TTS) was not reached. Methods: The ECA was developed using NHS data for VHL RCC patients undergoing active surveillance at the US National Cancer Institute with up to 5 years of follow-up. Key LS-004 eligibility criteria (e.g., no prior systemic therapy or metastasis) were applied. Propensity score (PS) weighting was used to balance baseline characteristics (age, sex, number and size of RCC, prior surgery and time from prior surgery, VHL mutation status) between LS-004 and ECA, with balance evaluated using standardized mean difference (SMD). PS adjusted point estimates and 95% CI for ORR, assessed by independent blinded committee review using RECIST 1.1, and TTS were estimated. For the ECA, the ORR was evaluated among patients with ≥3 serial scans to allow the opportunity for a confirmed response. Results: The ECA included 244 patients with 178 patients in the ORR analysis. Prognostic factors were well balanced between the ECA and LS-004 with a SMD<0.1 for all covariates. The PS adjusted ORR (95% CI) for LS-004 and the ECA was 63.9% (51.9, 76.0) and 1.5% (0.0, 3.3), respectively. Median (95% CI) TTS was 44.4 (35.7, 51.1) months in the ECA, and not yet reached in LS-004. Conclusions: The magnitude of the treatment effect with belzutifan is large compared with the ECA. Although residual confounding is still possible, including effects of unmeasured confounders, observing such a large effect is unlikely due to chance. The results support the demonstrated antitumor activity and efficacy of belzutifan in the treatment of VHL RCC.

Surgical variables and risk factors associated with urinary leak following partial nephrectomy: Insights from a high-risk population.

Journal of Clinical Oncology Milan Patel, Lauren Loebach, Ruben Blachman-Braun et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.604

604 Background: Urinary leak (UL) is a common complication following partial nephrectomy (PN). This study aims to identify the risk factors and surgical variables associated with the development of UL following PN in a cohort that includes a significant number of patients with hereditary renal cancer syndromes, multiple tumors, and a history of prior PNs. Methods: A retrospective chart review was conducted to identify patients who underwent PN at our institution from January 2006 to December 2023. Clinical, demographic, and surgical characteristics were recorded and analyzed. Statistical analysis was performed with SPSS v.29.0. Results: A total of 1173 PNs were analyzed, of which 89 (7.6%) had a UL. Patients had a median age at time of surgery of 50 [Interquartile range (IQR): 38 - 59] years, and 3 [IQR: 1 - 6] tumors removed per procedure. The robotic approach was utilized in 61.6% of cases, and the most common diagnosis was von Hippel-Lindau disease (47.4%). The frequency of UL was 5.1% for first-time PN, 10.4% for second, and 19.6% for third. Multivariable-adjusted analysis demonstrated an increased risk of UL with 3 rd PN (OR 2.379; p = 0.013), higher intraoperative estimated blood loss (per 100mL: OR 1.016; p = 0.006) and a decreased risk with robotic approach (OR 0.376; p < 0.001). (Table) Overall, 98.9% of UL cases (88 patients) were successfully managed with conservative management (post-op drain and foley), ureteral stent placement, percutaneous drain, or nephrostomy tube. Conclusions: In this cohort, UL is associated with the complexity of the surgery (repeat PN and higher EBL). A robotic approach had a lower risk of UL, while all but one UL were effectively managed non-operatively. Future research should investigate intraoperative and postoperative strategies to minimize this complication. Multivariable-adjusted logistic regression analysis evaluating the association between clinical variables and urinary leak after partial nephrectomy.* OR 95% CI p-value Partial nephrectomy count 1 1 2 1.693 0.973 - 2.944 0.062 3 2.379 1.200 - 4.714 0.013 ≥ 4 1.121 0.326 - 3.848 0.856 Surgical approach Open 1 Laparoscopic 0.324 0.042 - 2.517 0.281 Robotic 0.376 0.225 - 0.631 < 0.001 EBL (per 100 mL) 1.016 1.004 - 1.028 0.006 CI: Confidence interval, EBL: Estimated blood loss, OR: Odds ratio. *Analysis conducted using variables listed as well as age, gender, kidney laterality, race, ethnicity, presence of solitary kidney, surgical technique, total number of tumors removed, and size of largest tumor removed.

Evolution of point defects in Bi2Te3-based materials and performance of thermoelectric modules subjected to <i> <b>γ</b> </i>-irradiation

Applied Physics Letters Yixiao Deng, Wenbin Qiu, Kaiyi Luo et al. Feb 10, 2025 DOI: 10.1063/5.0245402

Bismuth telluride (Bi2Te3), renowned for its exceptional thermoelectric (TE) properties near room temperature, is used in extreme environments such as deep space exploration, leading to extensive attention on the radiation-induced defects to Bi2Te3. However, the evolution of point defects during gamma (γ)-irradiation is still poorly understood. In this paper, we report the evolution of point defects in Bi2Te3 materials subjected to varying doses of γ-irradiation and their impact on TE performance. Precisely, Bi0.5Sb1.5Te3 and Bi2Te2.7Se0.3 materials, along with TE modules, were fabricated and subsequently subjected to γ-irradiation. The segregation of Te elements in Bi2Te3 was observed under low irradiation dose, attributing to the formation of interstitial atom–vacancy pair of Te induced by γ-irradiation. In addition, the formation of point defects has a positive relation with the irradiation dose. The positron annihilation (PA) measurements revealed that the number of vacancies in Bi2Te3 diminished with increasing irradiation dose. The accompanying changes in carrier concentration (nH) and mobility (μH) suggest that γ-ray drives Bi atoms to occupy Te vacancies, forming antisite defects. The TE performance of Bi2Te3 was subsequently evaluated, and the findings revealed a strong correlation with the evolution of point defects. This study provides insights into the damage mechanisms and property alterations of Bi2Te3 materials under γ-irradiation.

Identifying modifiable factors that influence walking in patients undergoing surgery for neurogenic claudication: a prospective longitudinal study

Scientific Reports Suzanne McIlroy, Lindsay Bearne, John Weinman et al. Feb 10, 2025 DOI: 10.1038/s41598-025-87894-9

Racial disparities in renal cell carcinoma histology and outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191).

Journal of Clinical Oncology Xiaofan Lu, Jean-Christophe Bernhard, François Audenet et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.442

442 Background: In the U.S., racial disparities in renal cell carcinoma (RCC) are documented for common histologies, highlighting differences in incidence and outcomes between Black and non-Black patients. Such disparities are underexplored in European populations, especially across a broader histology spectrum within a universal healthcare system. We aim to investigate racial disparities in RCC histologies and their outcomes among Black and non-Black patients in France. Methods: We conducted a retrospective cohort study utilizing the UroCCR database, spanning from March 1957 to May 2024. This multicenter study, referred as UroCCR-191, involved 30 tertiary centers in France, analyzing 9,404 patients (338 Black and 9,066 non-Black) with confirmed histology. Patients with unknown racial background or unidentified/multiple histologies were excluded. Histological distribution, demographics, clinical presentations, tumor features, and outcomes were compared. Results: Clear cell RCC (ccRCC) was more prevalent among non-Black patients (68.8% vs 47.6%; odds ratio [OR]: 2.4, p &lt; 0.001). Non-clear cell histologies were more common in Black patients, including papillary RCC (23.1% vs 11.8%, p &lt; 0.001), the rare clear cell papillary renal cell tumor (1.5% vs 0.5%, p = 0.044), and other rare molecularly-defined histologies such as translocation RCC (2.1% vs 0.6%, p = 0.005), FH-deficient RCC (0.6% vs 0.1%, p = 0.067) and renal medullary carcinoma (0.3% vs 0, p = 0.001); all with OR ≥2 and a false discovery rate &lt;0.15. Black patients were younger at diagnosis, with earlier-stage tumors and higher rates of partial nephrectomy. No significant differences were observed in cancer-specific survival; however, Black patients showed better distant recurrence-free survival (hazard ratio [HR]: 0.55, p = 0.020). Race was not an independent prognostic factor when accounting for other clinical variables (Table). Conclusions: Black patients in France exhibit higher incidences of non-clear cell RCC and are diagnosed at earlier stages compared to non-Black patients. The absence of race as an independent prognostic factor, unlike U.S. data, highlights the potential influence of healthcare systems in modulating racial disparities. This underscores the need for tailored RCC management that considers racial backgrounds to refine diagnosis and outcomes. Hazard ratios using multivariate Cox regression for predictors of distant recurrence-free survival. Variable Reference group Comparison group HR 95% CI p -value Race non-Black Black 0.96 0.51-1.79 0.889 Age (years) ≤63 &gt;63 1.25 1.07-1.47 0.005 Sex Female Male 1.29 1.09-1.53 0.004 Nephrectomy type Partial Radical 2.98 2.46-3.61 &lt;0.001 T stage T1 + T2 T3 + T4 2.36 1.96-2.85 &lt;0.001 N stage N0 N1 + N2 2.84 2.25-3.58 &lt;0.001 Fuhrman grade 1 + 2 3 + 4 2.39 1.97-2.91 &lt;0.001 Histology ccRCC non-ccRCC 0.81 0.65-1.01 0.062

CUPID ( <sup>64</sup> Cu-TLX592 phase I PK, biodistribution and dosimetry): A proof-of-concept study of TLX592-targeted alpha therapy in prostate cancer.

Journal of Clinical Oncology Nat Lenzo, Anne Capp, Aviral Singh et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.177

177 Background: Antibody-based PSMA-targeting therapies have potential to overcome limitations of small molecule approaches such as undesirable off-target side effects. TLX592 utilizes RADmAb technology engineered to optimize clearance rates while retaining advantages of antibody-based approaches including high target selectivity &amp; rapid internalization. 225 Ac is a high energy emitter with a short path length. 225 Ac-PSMA-RADmAb is a "next generation" targeted alpha therapy for patients with prostate cancer (PC) who progress after 177 Lu-based therapy. We report preliminary results from an open-label, first-in-human mass dose escalation study of TLX592 in patients with advanced PC. To demonstrate proof-of-targeting, copper-64 ( 64 Cu), detectable by PET, was used as a surrogate for 225 Ac. Methods: 11 patients with PC confirmed with PSMA imaging as either oligometastatic (≤5 metastatic lesions; Groups 1-3, dose escalation) or higher tumor burden (≥10 metastatic lesions; Group 4) were assigned to the following: 1) 300 MBq, 2mg 64 Cu-TLX592 (n=3); 2) 300 MBq, 2mg 64 Cu-TLX592+8mg unlabeled TLX592 (10mg mass dose; n=3); 3) 300 MBq, 2mg 64 Cu-TLX592+18mg unlabeled TLX592 (20mg mass dose; n=2); or 4) 300 MBq, 2mg 64 Cu-TLX592+18mg unlabeled TLX592 (20mg mass dose, based on dose escalation results; n=3). PET/CT scans were performed 1h±5, 4±0.5h, &amp; 20±4h after infusion for Groups 1-3 &amp; 4h±0.5h, 20±3h &amp; 48±4h after infusion for Group 4. Blood samples were collected before each imaging period, &amp; vital signs were collected before infusion, after infusion, 1h after infusion, &amp; prior to each imaging period. The primary endpoint was tumor-to-healthy tissue SUV &amp; residence times. Secondary endpoints included safety assessments &amp; absorbed radiation doses. Results: TLX592 blood clearance was more rapid than TLX591 (T ½ =19.86+1.96, T ½ =33.65+11.04h, resp.) with similar organ uptake. TLX592 circulating levels increased with mass dose. Whole-body effective dose (mean±SD mSv/MBq) was 0.043±0.007 &amp; 0.042±0.002 in Groups 3 &amp; 4, resp. Residence times for Groups 3 &amp; 4 are shown (Table). At 20h, TLX592 uptake in bone lesions in Group 4 correlated with 68 Ga-PSMA-11 uptake (r=.756, P =.003). No serious adverse events were observed. Conclusions: Preliminary results demonstrate successful proof-of-concept of RADmAb technology, intended for use with therapeutic alpha-emitting radionuclides. Rapid antibody clearance has potential to minimize radiation exposure &amp; augment the safety &amp; tolerability profile of antibody-based therapies. Clinical trial information: NCT04726033 . Residence times (mean±SD) MBq.hr.MBq -1 . Source Organ Group 3 Group 4 Kidneys 0.305±0.059 0.370±0.064 Liver 5.440±1.188 5.443±0.771 Lungs 0.890±0.139 1.227±0.184 Salivary glands 0.005±0.001 0.006±0.003 Bone/red marrow 0.576±0.424 0.513±0.218 Spleen 0.444±0.104 0.470±0.201 Remainder of body 7.615±0.049 9.990±0.448

Impact of the 2012 and 2018 USPSTF statements on prostate cancer screening and metastatic rates in Kaiser Permanente Northern California.

Journal of Clinical Oncology Joseph Presti, Brandon Horton, Stacey Alexeeff et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.359

359 Background: To assess how the United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Statements of 2012 (Grade D - “recommends against”) and 2018 (Grade C - “selectively offering...based on professional judgment and patient preferences”) influenced race-specific rates of PSA screening and metastatic cancer at presentation among screen-eligible men in Kaiser Permanente Northern California. Methods: This is a retrospective study from 2006 to 2022, in screen-eligible (ages 50-69), Kaiser Permanente Northern California members. We compared the race-specific rates of PSA screening and metastatic cancer at presentation before and after the changes in the USPSTF Statements. Results: In 2006 there were 324,950 screen-eligible men (11% Black, 17% Asian, 73% White). In 2022 there were 434,705 screen-eligible men (11% Black, 27% Asian, 63% White). Race-specific, annual screening and metastatic rates are shown (Table). Following the 2012 USPSTF statement, all races experienced similar declines in screening and an increase in metastatic rates which was greatest among Black men. Following the 2018 statement, all races experienced similar increases in screening (with the exception of the time around the pandemic in 2020); yet as of 2022, the rate of metastatic cancer has continued to increase. Conclusions: The 2012 USPSTF Statement (Grade D) was associated with a decline in screening and an increase in metastatic rates among all races, yet was greatest among Black men, a high-risk group. Following the 2018 USPSTF Statement (Grade C), screening rates have increased yet metastatic rates continue to rise and remains greatest among Black men. Biennial race-specific screening and metastatic rates. 2006 2008 2010 2012 2014 2016 2018 2020 2022 Screening Rates(per 100,000 person-yrs) Asian 477 511 512 453 406 370 380 262 432 Black 441 452 468 398 364 328 338 255 381 White 438 461 455 398 354 315 329 242 384 Metastatic Rates(per 100,000 person-yrs) Asian 0.06 0.22 0.08 0.06 0.12 0.20 0.25 0.16 0.34 Black 0.44 0.34 0.33 0.31 0.66 0.76 0.85 0.72 1.18 White 0.26 0.23 0.19 0.17 0.30 0.31 0.42 0.48 0.73

Characterizing the activity of inflammasome genes and their association with oncological outcomes in prostate cancer.

Journal of Clinical Oncology Alireza Ghoreifi, Mohammed Alshalalfa, Elai Davicioni et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.410

410 Background: Inflammasomes are multiprotein complexes that regulate inflammation-associated signaling pathways. Although inflammation plays a crucial role in cancer cell proliferation, the specific role of inflammasomes in prostate cancer (PCa) remains underexplored. This study aims to elucidate the expression of inflammasome-related genes in PCa and assess their association with clinical outcomes. Methods: De-identified transcriptome data from a cohort of 52,266 radical prostatectomy (RP) samples tested (2016-2024) with the Decipher prostate genomic classifier (Veracyte, San Diego, CA) were retrieved from the GRID registry (NCT02609269). Expression analysis focused on 33 genes involved in inflammatory pathways. Outcomes analysis was conducted on a retrospective cohort of 855 patients treated with RP (META855), using Cox regression analysis, adjusting for baseline pathological characteristics. Results: Analysis of baseline gene expression in the GRID RP cohort revealed that most genes exhibit low baseline expression, whereas HSP90AB1, APP, TXN, and TXNIP demonstrate strong expression signals. Higher expression of most genes was associated with higher rate of Gleason grade group 4 or 5 in the GRID RP cohort. On survival analysis of the META855 cohort, higher expression (top 25%) of AIM2 and HSP90AB1 were associated with worse metastasis-free survival (p&lt;0.05 for both). Conversely, both high and low expression levels of NLRP3 were associated with better metastasis-free survival outcomes following RP compared to average expression (p&lt;0.05). On multivariable Cox regression analysis, adjusting for grade group, seminal vesicle involvement, lymph node involvement, and margin status, higher expression of AIM1 (HR 1.75) and HSP90AB1 (HR 1.60) were significantly associated with shorter time to metastasis following RP (p&lt;0.05 for both). Conclusions: There is a molecular heterogeneity within pro-inflammatory genes among patients with PCa.Our findings showed thathigher expression of HSP90AB1 is linked to poorer oncological outcomes, whereas both high and low expression levels of NLRP3 are associated with better outcomes following RP.Further refinement is required to build a robust signature, along with external validation of these findings in other cohorts.

The effect of transcranial random noise stimulation (tRNS) over bilateral parietal cortex in visual cross-modal conflicts

Scientific Reports Jiahong Cui, Wenbo Yu, Lei Hu et al. Feb 10, 2025 DOI: 10.1038/s41598-025-85682-z

Second-line platinum-based chemotherapy (PBT) in patients with metastatic urothelial carcinoma (mUC) treated with first-line pembrolizumab plus enfortumab vedotin (P/EV): A single-center, retrospective study.

Journal of Clinical Oncology Junkyu Kim, Se Hoon Park, Changgon Kim et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.785

785 Background: Although the efficacy of PBT as first-line therapy for mUC has been known for more than 30 years, the recent integration of P/EV as a preferred first-line option prevented the use of evidence-based regimen. Since the available second-line regimens depend on what was given as first-line, we evaluate the efficacy and tolerability of second-line PBT in mUC patients treated with first-line P/EV. Methods: We retrospectively reviewed the medical records of 37 patients with mUC who were treated with first-line P/EV, mostly in clinical trials, between Jan 2022 and Jan 2024 at Samsung Medical Center (Seoul, Korea). Patients with mUC whose disease progressed during or after first-line treatment with P/EV received PBT involving gemcitabine plus either cisplatin or carboplatin (determined on the basis of cisplatin-eligibility). Primary endpoints included safety and response rates. Results: Among a total of 37 first-line P/EV patients, 10 received second-line PBT: gemcitabine plus cisplatin (n = 8) and plus carboplatin (n = 2). The median age was 68 years (range, 48 to 82 years) and the median interval from the last dose of P/EV was 50 days (range, 15 to 89 days). A total of 33 PBT cycles were given (median, 2; range 1 to 6). One patient achieved a complete response and 3 had a stable disease. Although peripheral neuropathy and gastrointestinal toxicities were the most frequently encountered adverse events, safety profile was generally manageable. Median progression-free and overall survivals were 3.4 months (95% CI, 2.3 to 4.5) and 8.0 months (95% CI, 6.1 to 19.9), respectively. Conclusions: Second-line PBT for mUC patients treated with first-line P/EV does not appear highly active but the observation of responders merits further studies in those with medically-fit, platinum-eligible patients.

Time to real-world progression (TTrwP) among patients (pts) with relapsed/refractory (R/R) testicular germ cell tumors (GCT) undergoing palliative chemotherapy (CT) in the United States (US).

Journal of Clinical Oncology Darren R. Feldman, Patrick Gagnon-Sanschagrin, Jessica Maitland et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.628

628 Background: Pts with R/R testicular GCT are considered to be incurable, having experienced progressive disease (PD) after salvage conventional-dose CT (CDCT) and/or high-dose CT (HDCT). Therapeutic options are limited to palliative CT, with an estimated real-world (rw) overall survival of 8 months from initiation of their first palliative CT regimen. Understanding TTrwP may help further inform clinical care. Methods: The Komodo Research Database (KRD; 01/2016-03/2023) was used to identify adult males in the US with testicular GCT who received palliative CT after salvage CT. TTrwP was estimated using Kaplan-Meier analysis and defined as time from index date (initiation of first palliative CT regimen) to first rw proxy of PD, which included 1) radiation after the first cycle of palliative CT, 2) treatment addition/switch, 3) treatment discontinuation prior to death, 4) hospice admission, or 5) death. Treatments received pre-/post index were described. Results: Among 248 pts receiving palliative CT, 97 (39.1%) had sufficient data to confirm prior salvage CT and, of those, 80 (82.5%) had ≥12 months of potential follow-up for outcome assessment. Median age was 33.0 years and most pts had commercial (51.3%) or Medicaid (42.5%) coverage. Before index, 49 (61.3%) pts were exposed to HDCT with or without CDCT (+/- CDCT) and 31 (38.8%) pts to CDCT only. Index regimens included gemcitabine-oxaliplatin (47.5%), oral etoposide (13.8%), gemcitabine-paclitaxel (13.8%), and gemcitabine-oxaliplatin-paclitaxel (7.5%). Median (95% confidence interval) TTrwP was 3.8 (2.6-4.7) months overall, 3.5 (2.3-4.7) months after prior HDCT +/- CDCT, and 4.0 (1.7-6.6) months after CDCT only. First PD events included radiation (32.5%), treatment discontinuation (31.3%), and treatment addition/switch (22.5%), occurring at a median of 2.8, 2.1, and 4.7 months from index, respectively. Death was observed for 91.3% of pts and occurred at a median of 2.4 months from PD event, including 3 (3.8%) pts with death as their PD event (Table). Conclusions: This study is the first to use rw proxies for PD in claims data to estimate TTrwP in pts with R/R testicular GCT. With no curable treatment options remaining, the short TTrwP highlights the poor outcomes in this patient population and need for novel therapies to improve clinical outcomes. RW PD events observed in pts with R/R GCT (N=80). First PD event N (%) Time to event (months), median [IQR] Death, N (%) Time from PD event to death (months), median [IQR] Radiation 26 (32.5%) 2.8 [1.4 - 4.6] 26 (100.0%) 3.0 [1.9 - 6.3] Treatment discontinuation 25 (31.3%) 2.1 [1.0 - 3.9] 25 (100.0%) 1.8 [1.3 - 3.1] Treatment addition/switch 18 (22.5%) 4.7 [3.0 - 6.1] 16 (88.9%) 3.8 [3.2 - 6.1] Hospice 3 (3.8%) 9.9 [0.5 - 17.1] 3 (100.0%) 0.3 [0.3 - 3.0] Death 3 (3.8%) 30.4 [3.8 - 32.0] 3 (100.0%) 0.0 [0.0 - 0.0] No PD 5 (6.3%) – 0 (0.0%) –

Results of a cross-sectional survey to explore determinants of health-promoting activities among Hispanic/Latino (H/L) patients (pts) with prostate cancer (PCa) on androgen deprivation therapy (ADT).

Journal of Clinical Oncology Sharon H. Choi, Frances Ramos Diaz, Kristine Ly et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.321

321 Background: H/L pts with PCa are at an increased risk of developing ADT-related side effects. Diet and exercise can improve PCa-related outcomes, including reducing ADT-related toxicities. However, little is known about individual perspectives on factors impacting engagement in health-promoting behaviors among H/L men with PCa. Methods: We developed a survey to examine sociodemographic characteristics, exercise/dietary habits, motivation for change, and barriers to participate in lifestyle interventions. We surveyed pts with PCa who self-identified as H/L ethnicity, treated at UCSD, and who were either previously or currently on ADT at the time of the survey. Questionnaires were administered in Spanish or English, either in person or by telephone, using interpreter services based on pt preference. Results: Between April and August 2024, 61 pts (median age 66 years) completed the survey with an 88% response rate. Most pts were of Mexican descent (85%), born outside the U.S. (72%), had public health insurance (51%), resided in disadvantaged neighborhoods (54%) based on the Area Deprivation Index, from H/L ethnic enclaves (64%), and were primarily Spanish speakers (51%), with 36% reporting no English proficiency. About half (49%) reported household financial distress, yet 92% felt supported by their community or family during PCa diagnosis. At the time of the survey, 85% of pts were on ADT, 68% had distant metastasis, and 69% had undergone local therapy. Most had a BMI ≥ 30 kg/m2 (52%), diabetes (51%), and 66% had a history of coronary artery disease or a high-risk atherosclerotic cardiovascular disease score of ≥ 20%. Most pts (51%) reported limited dietary monitoring and 71% reported less than 50 min/week of moderate-intensity exercise, with 41% not engaging in any moderate exercise. However, most expressed motivation to initiate lifestyle changes (91% exercise; 83% diet) and 82% showed interest in joining a community lifestyle intervention program. Pts identified participation incentives including family involvement (73%), other H/L participants (77%), Spanish-speaking staff (86% among Spanish speakers), and a driving distance of less than 5 miles. Conclusions: We report that H/L pts with PCa on ADT have substantial cardiometabolic risk factors. While engagement in health-promoting activities was limited, patients expressed motivation to improve health-promoting practices, with actionable incentives to enhance participation, underscoring the need for tailored intervention to mitigate ADT toxicity in this pt population. These findings will inform the design of an interventional study that examines the impact of a combined group exercise and nutrition counseling intervention on physical fitness and cardiovascular health among H/L men with PCa on ADT.

Utility of extended interval dosing of denosumab in patients with metastatic prostate cancer.

Journal of Clinical Oncology Stephanie Schneck, Rebecca Hassoun, Sandra K. Althouse et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.68

68 Background: Bone modifying agents, such as zoledronic acid and denosumab, are commonly used in patients (pts) with metastatic solid tumors to reduce the incidence of skeletal-related events (SREs). The FDA-approved administration schedule for both agents is every 4 weeks, however less frequent administration (i.e. every 12 weeks) is commonly observed in practice due to patient convenience. The efficacy and safety of these extended interval regimens is well-established for zoledronic acid, however there is little evidence available supporting this practice with denosumab. Methods: Pts with metastatic prostate cancer were evaluated for development of SREs during treatment with extended intervals of denosumab. 103 pts evaluated and treated at Indiana University Health between September 2019 and September 2024 were included in this analysis. A historical control group of pts receiving every 4-week dosing was used as comparison (1). SREs were defined as pathologic fracture, spinal cord compression, operation, or radiation to bone. Extended interval dosing is defined as an administration schedule &gt;4 weeks apart on a consistent basis. Results: Median age at starting bone preserving agent was 70.6 years (range, 49.5-90). 24 pts (23.3%) had metastatic castration-sensitive prostate cancer and 79 pts (76.7%) had metastatic castration-resistant prostate cancer (mCRPC) at time of last follow-up. Incidence of SREs in all patients receiving extended interval denosumab was 23.3%. The incidence of SREs in patients with mCRPC receiving extended interval dosing was 26.6%. This compares favorably to historical data with incidence of SRE in the every 4 weeks dosing group at 35.9% (p=0.10). Median time to development of SRE was not estimable when all patients in the denosumab extended interval group were included in analysis. Median time to SRE in the mCRPC extended interval dosing group was 42.8 months and 20.7 months in the historical every 4-week dosing group (p&lt;0.01). SREs identified for all patients receiving extended dosing interval denosumab were pathologic fracture (3, 2.9%), spinal cord compression (1, 1.0%), surgery (2, 1.9%), and radiation to bone (22, 21.4%). Conclusions: Our findings suggest that extended interval dosing of denosumab in patients with metastatic prostate cancer is not associated with an increased risk of development of SREs and may offer convenience for pts. Larger prospective studies are needed to validate these findings. 1. Fizazi K, Carducci M, Smith M, et al. Lancet 2011; 377: 813–822.

Gene network analysis identifies dysregulated pathways in an autism spectrum disorder caused by mutations in Transcription Factor 4

Scientific Reports Lucas M. de Carvalho, Vinicius M. A. Carvalho, Antonio P. Camargo et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89334-0

Recent treatment patterns in US-based real-world patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology Umang Swami, Yeonjung Jo, Zeynep Irem Ozay et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.104

104 Background: Androgen deprivation therapy (ADT) intensification [ADT + androgen receptor-pathway inhibitor (ARPIs) +/- docetaxel] has been shown to improve survival outcomes in pts with mHSPC and is recommended as standard of care by all major guidelines. However, prior studies have shown underutilization of ADT intensification [PMID: 39191549]. There are limited updated and large-scale studies on the use of ADT intensification, beyond January 2023. In this study, we aimed to assess the treatment patterns of ADT intensification in real-world pts with mHSPC in the US, including data on those treated since January 2023. Methods: This retrospective study utilized the nationwide Flatiron Health Electronic Health Record (EHR) derived de-identified database. Eligibility: Pts diagnosed with mHSPC and availability of treatment information (ADT and/or line of therapy in mHSPC). The data cut-off date was 5/31/2024. Treatment patterns were summarized using frequency and percentages. All analysis was done using R version 4.2.3. Results: Among 24,105 pts with metastatic prostate cancer in the database, a total of 14,084 were eligible and included. The median age at metastatic diagnosis was 72 years (IQR 65 – 79), and 60% were White non-Hispanic. In the overall cohort (1/1/2013–5/15/2024), 56.8% received ADT monotherapy, and 37.7% received ADT intensification. Table summarizes the treatment patterns by year, highlightinga consistent increase in adoption of intensified ADT regimens, and a decline in use of ADT monotherapy. Notably, since January 2023, 76.8% pts with mHSPC received ADT intensification while only 17.3% of pts received ADT monotherapy. Conclusions: To our knowledge, this is the first and largest study to evaluate the current use of ADT intensification. These data indicate a notable improvement in the adoption of level 1 evidence (ADT intensification) in the treatment of pts with mHSPC. These encouraging data emphasize the benefits of continued efforts to promote guideline-concordant care and provide the current treatment landscape to design clinical trials. Treatment patterns by year in pts with mHSPC. Treatment 2013–2017n = 5,263(%) 2018n = 1,313 (%) 2019n = 1,407(%) 2020n = 1,353(%) 2021n = 1,483(%) 2022n = 1,556(%) 2023n = 1,459(%) 2024n = 250(%) ADT monotherapy 4,095 (77.8) 856 (65.2) 819 (58.2) 664 (49) 698 (47.1) 569 (36.6) 291 (20) 5 (2) ADT + ARPI 155 (2.9) 238 (18) 354 (25.1) 452 (33) 555 (37.4) 695 (44.7) 842 (58) 154 (61.6) ADT + Docetaxel 709 (13.5) 156 (12) 175 (12.4) 156 (12) 134 (9.0) 117 (7.5) 78 (5.3) 19 (7.6) Triplet(ADT + ARPI + Docetaxel) 6 (0.1) 2 (0.2) 1 (0.1) 2 (0.1) 9 (0.6) 82 (5.2) 166 (11.1) 53 (21.2) Other therapies 298 (5.7) 61 (4.6) 58 (4.1) 79 (5.8) 87 (5.9) 93 (6) 82 (5.6) 19 (7.6)

Effectiveness and safety of radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC): A systematic literature review of 48 real-world studies.

Journal of Clinical Oncology Michaela Lunan, Amit D Raval, Nguyen Thi Nhan Phan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.81

81 Background: Radium-223 (Ra-223) has been approved for men with mCRPC with bone metastases since 2013. However, as the treatment landscape has significantly changed in the last decade, a comprehensive understanding of Ra-223's real-world outcomes could inform on treatment choice in routine clinical practice. This systematic literature review aims to fill this gap by summarizing the real-world (RW) effectiveness and safety in men with mCRPC treated with Ra-223. Methods: Electronic databases (PubMed, Embase, the Cochrane Library, trial registers) and the past-two years of relevant conferences were searched systematically for RW observational studies examining outcomes of Ra-223 in men with mCRPC published between 2014 and March 2024. Study results of interest included Ra-223 treatment pattern, real-world overall survival (rwOS) and progression-free survival (PFS), pain response, change in alkaline phosphatase (ALP) or prostate-specific antigen (PSA), and safety outcomes (any or grade 3+ skeletal-related events, myelosuppressive adverse events). Results: From 1085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n=39) from Europe (n=22) and North America (NA) (n=18), with sample size ranging from 104 to 1,628. Median age mostly ranged from 68 to 76 Ten studies reported tumor burden and included ≥ 25% of cohort with 20+ metastases. Over 50% of Ra-223 cohort received prior chemotherapy in 23 studies, and 50% received prior ARPIs in 22 studies. Most studies in NA and Europe reported ≥ 55% and 64% completion of ≥ 5 cycles of Ra-223, respectively. Earlier line, no prior chemotherapy or immunotherapy, hemoglobin and neutrophils within lower standard limit were key factors associated with completion of ≥5 cycles of Ra-223. Median rwOS varied widely from 11 to 24 months with two exceptions and nearly a 1/3 rd reporting 15 months or longer. Completion of ≥ 5 cycles was associated with a 2 to 5-fold increase in the median rwOS. PFS ranged from 4.3 to 7.3 months with a median of 2 prior lines in the 7 studies reporting. 12 studies reporting pain outcomes showed a reduction in pain with varying magnitude. Of 13 studies reporting grade 3+ myelosuppression, incidence varied from 1-22%. Out of 14 studies reporting fractures, the incidence was &lt;10% in most studies (N=12) with trends toward lower rates with bone health agent (BHAs) use. Conclusions: This is the most up-to-date and comprehensive review of the effectiveness and safety of Ra-223 in a modern era with more widespread use of ARPIs post landmark ALSYMPCA trial for Ra-223. Findings highlight the survival benefits of early use of Ra-223 with the completion of 5 or more cycles, along with a favorable safety profile and low rates of fracture when guideline recommended BHAs are used.

Efficacy and safety of nanosomal docetaxel lipid suspension in Indian patients with metastatic castration-resistant prostate cancer (mCRPC): A multicenter, open-label, single-arm phase 4 study.

Journal of Clinical Oncology Prabrajya NARAYAN Mohapatra, Bharat Vaswani, Padmaj Sudhakar Kulkarni et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.168

168 Background: Docetaxel combined with prednisone is the first line chemotherapy to improve overall survival in metastatic castration resistant prostate cancer (mCRPC). Nanosomal docetaxel lipid suspension (NDLS) is a novel formulation that eliminates the need for polysorbate 80 and ethanol, reducing infusion-related reactions and the requirement for steroid premedication. This phase 4 trial aims to assess the efficacy and safety of NDLS in patients with mCRPC. Methods: In this multicenter, open-label, single-arm trial, patients with confirmed mCRPC and at least one measurable lesion were enrolled. Exclusions included those with brain lesions or a history of hypersensitivity to taxanes. NDLS was administered at 75 mg/m 2 every three weeks for 10 cycles without steroid premedication. The primary endpoint was the overall response rate (ORR) upon completion of 10 cycles. Results: Between July 2018 and July 2023, 86 patients (safety set) received the study drug. The modified intention-to-treat (mITT) set (included 77 patients who received at least one dose and had at least one efficacy evaluation). The mean age of the mITT set was 67 (±6.2) years, with a median prostate specific antigen (PSA) value of 31.3 ng/mL. At the end of 10 cycles, the overall response rate (ORR) was 16.9% (95% CI: 9.31, 27.14), and the disease control rate (DCR) was 44.2% (95% CI: 32.84, 55.93). A ≥50% reduction in serum PSA was observed in 36 (46.8%) patients. The visual analog score (VAS) decreased significantly from baseline with a mean difference of 12.8 mm (P&lt;0.0001). Median progression free survival (PFS) was 12 months (95% CI: 8.12, 18.12), and the overall survival rates at 1 and 2 years were 31.2% and 19.5% respectively. Adverse events were reported in 64 (84.4%) patients, with only one patient experiencing a grade ≥3 adverse event. Common grade 1/2 adverse events (≥10% of patients) included diarrhea, vomiting, asthenia, alopecia, headache, anemia, fever, infections, and pain. Conclusions: NDLS showed efficacy and safety in patients with metastatic castration-resistant prostate cancer. Clinical trial information: CTRI/2018/02/012212 . Efficacy outcomes at cycle 10 completion. Parameter mITT set (N=77) PR, n (%) 13 (16.9) SD, n (%) 21 (27.3) ORR, (95% CI) 16.9% (9.31, 27.14) DCR, (95% CI) 44.2% (32.84, 55.93) BOR, (95% CI) 26.0% (16.64, 37.23) ≥50% reduction in serum PSA, n (%) 36 (46.8) Change from baseline for VAS (mm), mean (±SD) 12.8 (±22.11) (p&lt;0.0001) Median PFS (months), (95% CI) 12 (8.12, 18.12) Median OS (months) Not reached PR: partial response; SD: stable disease; BOR: Best overall response.

Comprehensive investigation of CPSF3's role in the progression of bladder cancer.

Journal of Clinical Oncology Zhiyang Ma, Danfeng Xu, Chenghe Wang Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.829

829 Background: Bladder cancer (BC) is a global health issue, with a significant number of new cases diagnosed annually. Despite advances in treatment, many patients experience recurrence or progression, emphasizing the need for novel prognostic biomarkers and therapeutic targets. This study aimed to investigate the prognostic significance and biological function of Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) in BC. Methods: We analyzed CPSF3 expression using The Cancer Genome Atlas (TCGA) data and immunohistochemistry (IHC) on a cohort of 203 BC patients. A nomogram incorporating CPSF3 expression was constructed to predict overall survival (OS) and disease-free survival (DFS). In vitro experiments were conducted to assess the effect of CPSF3 knockdown on BC cell proliferation, colony formation and cell cycle distribution. Bioinformatics analyses, including Gene Set Enrichment Analysis (GSEA) and immune infiltration analysis, were performed to explore potential mechanisms. Results: High CPSF3 expression was significantly associated with poor OS and DFS in TCGA and our cohort. The nomogram incorporating CPSF3 showed superior predictive performance compared to traditional models. Downregulation of CPSF3 inhibited BC cell proliferation, colony formation and transition from G1 phase to S phase. GSEA revealed enrichment of oncogentic pathways in CPSF3 high-expression phenotype. CPSF3 expression was correlated with immune cell infiltration and expression of immune checkpoints in the tumor microenvironment. Conclusions: Our study demonstrates that CPSF3 is a promising prognostic biomarker for BC and may play a crucial role in BC progression. The nomogram incorporating CPSF3 expression provides an improved tool for predicting BC patient outcomes. These findings suggest that CPSF3 could be a potential therapeutic target for BC treatment.

Niacinamide and its impact on stratum corneum hydration and structure

Scientific Reports Thomas Sjöberg, Andebrhan Fsahaye, Emelie J. Nilsson et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88899-0

Abstract Niacinamide (NIA) is widely used in skincare for its favorable safety profile, anti-aging effects, and proven clinical efficacy in treating various skin conditions. However, its direct impact on the hydration and molecular organization of the stratum corneum (SC), the primary skin barrier, remains unclear. This study examines how NIA influences the SC’s lipid matrix organization, soft keratin structure, and water sorption behavior across varying relative humidity (RH) levels. Using small- and wide-angle X-ray diffraction and dynamic vapor sorption measurements, we compared NIA-treated SC samples to untreated controls under different RHs. The main findings show that while NIA is non-hygroscopic, it enhances water uptake of the SC at high humidity (95% RH). At low humidity (60% RH), NIA swells the keratin monomer spacing, although the SC water content remains low, suggesting a plasticizing effect that could increase SC flexibility in dry conditions. NIA also modifies the diffraction intensities from the lipid matrix differently at 60% and 95% RH, implying that it interacts with the SC lipid matrix and influences the water distribution within the SC lipid and protein domains. These effects appear independent of the investigated dose regime, indicating a specific concentration threshold. Overall, NIA shows distinct interaction with keratin, swelling the spacing between keratin monomers in dry conditions, without acting as a traditional keratolytic agent.

Optimizing DeepHRD Interpretability for Enhanced Clinical Decision Making

Journal of Clinical Oncology Hui Li, Qin Guo, Chengshan Guo Feb 10, 2025 DOI: 10.1200/jco-24-01870